Switch theme
Sign up to access all valuation multiples
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved, and commercializes the innovations through the sales of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.
2003
8
Last FY Revenue $0.2M
Last FY EBITDA -$0.7M
$22.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Karolinska Development achieved revenue of $0.2M and an EBITDA of -$0.7M.
Karolinska Development expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Karolinska Development valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$0.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -381% | XXX | XXX | XXX |
| EBIT | XXX | -$3.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1707% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.8M | XXX | XXX | XXX |
| Net Margin | XXX | -441% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Karolinska Development's stock price is SEK 1 (or $0).
Karolinska Development has current market cap of SEK 273M (or $28.1M), and EV of SEK 213M (or $22.0M).
See Karolinska Development trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22.0M | $28.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Karolinska Development has market cap of $28.1M and EV of $22.0M.
Karolinska Development's trades at 116.2x EV/Revenue multiple, and -30.5x EV/EBITDA.
Equity research analysts estimate Karolinska Development's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Karolinska Development's P/E ratio is not available.
See valuation multiples for Karolinska Development and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.1M | XXX | $28.1M | XXX | XXX | XXX |
| EV (current) | $22.0M | XXX | $22.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 116.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -30.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -6.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -33.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKarolinska Development's revenue per employee in the last FY averaged $24K, while opex per employee averaged $0.4M for the same period.
Karolinska Development's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Karolinska Development's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Karolinska Development and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -381% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $24K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1807% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Karolinska Development acquired XXX companies to date.
Last acquisition by Karolinska Development was XXXXXXXX, XXXXX XXXXX XXXXXX . Karolinska Development acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Karolinska Development founded? | Karolinska Development was founded in 2003. |
| Where is Karolinska Development headquartered? | Karolinska Development is headquartered in Sweden. |
| How many employees does Karolinska Development have? | As of today, Karolinska Development has 8 employees. |
| Who is the CEO of Karolinska Development? | Karolinska Development's CEO is Dr. Viktor Drvota, PhD. |
| Is Karolinska Development publicy listed? | Yes, Karolinska Development is a public company listed on STO. |
| What is the stock symbol of Karolinska Development? | Karolinska Development trades under KDEV ticker. |
| When did Karolinska Development go public? | Karolinska Development went public in 2011. |
| Who are competitors of Karolinska Development? | Similar companies to Karolinska Development include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Karolinska Development? | Karolinska Development's current market cap is $28.1M |
| Is Karolinska Development profitable? | Yes, Karolinska Development is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
